Alagille Syndrome Clinical Trial
Official title:
Validation of the ItchRO Diaries in Pediatric Cholestatic Liver Disease
The purpose of the study is to validate the ItchRO instrument (a clinical outcome assessment measure of itching) prior to the analysis of longitudinal treatment effect data being generated in ongoing clinical trials.
This research will examine the psychometric performance of the electronic diaries for the
itch-reported outcome (ItchRO) measure for both patients and caregivers in a stand-alone
2-week validation study in the target patient population. The study is non-interventional in
nature; the purpose of the study is to validate the ItchRO prior to the analysis of
longitudinal treatment effect data being generated in ongoing clinical trials. Following
training and initial completion of the electronic diaries, families will return home and
complete the diaries twice daily over the course of two weeks. Additional assessments include
the numerical rating scale to assess itching, the patient impression of change (PIC), the
caregiver impression of change (CIC), PedsQL (pediatric quality of life), children's sleep
habits questionnaire (CSHQ), and clinical scratch scale.
Longitudinal data will be used to follow the natural (non-interventional) course of the
disease and the quality of the data. Test-retest reliability will be assessed using diary
data from Day 1 to Day 14 in stable subjects as measured by the PIC for the child-completed
measure and the CIC for the caregiver measure. Convergent validity (correlations between the
ItchRO and similar concepts on the other measures included in the study) will also be
explored (such as the correlation between sleep and morning ItchRO diary scores). Clinical
validity (correlation between the ItchRO and clinician reports) and preliminary
responsiveness of those who changed in their itching status over the two week period will
also be assessed if sample sizes allow.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04729751 -
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
|
Phase 2 | |
| Active, not recruiting |
NCT05035030 -
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
|
Phase 3 | |
| Recruiting |
NCT06193928 -
Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
|
||
| Completed |
NCT02160782 -
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
|
Phase 2 | |
| Completed |
NCT00007033 -
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|
N/A | |
| Suspended |
NCT00571272 -
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
|
||
| Completed |
NCT02057692 -
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT02922751 -
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
|
||
| Completed |
NCT00001642 -
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome
|
N/A | |
| Recruiting |
NCT05488067 -
Atorvastatin Therapy on Xanthoma in Alagille Syndrome
|
Phase 4 | |
| Completed |
NCT04674761 -
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
|
Phase 3 | |
| Completed |
NCT02117713 -
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
|
Phase 2 | |
| Completed |
NCT02963077 -
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
|
Phase 1 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Completed |
NCT03082937 -
An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02047318 -
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
|
Phase 2 | |
| Completed |
NCT01903460 -
Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
|
Phase 2 | |
| Completed |
NCT01515631 -
Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review
|
||
| Enrolling by invitation |
NCT05846854 -
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
|
N/A | |
| Approved for marketing |
NCT04530994 -
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
|